ATAI LIFE SCIENCES N.V. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.91 USD | -1.55% |
|
-6.83% | +35.46% |
Presenter SpeechFlorian Brand (Executives)Good morning, everyone. I'm Florian Brand, the Co-Fo...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
ATAI Life Sciences NV is a Germany-based clinical-stage biopharmaceutical company. The Company engages in developing various treatments that focuses on various mental health disorders. The Company's therapeutic lead compound include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B receptor modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01, a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder.
Calendar
2024-08-11
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
1.91
USD
Average target price
11.8
USD
Spread / Average Target
+517.80%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +35.46% | 320M | |
| +29.03% | 49.18B | |
| -0.10% | 42.11B | |
| +43.45% | 40.37B | |
| -5.26% | 28.85B | |
| +11.48% | 26.09B | |
| -22.74% | 18.71B | |
| +9.06% | 13.26B | |
| +30.01% | 12.32B | |
| -1.51% | 11.99B |
- Stock Market
- Equities
- ATAI Stock
- News Atai Life Sciences N.V.
- Transcript : Atai Life Sciences N.V. - Special Call